Risk of Incident Antidepressant‐Treated Depression Associated with Use of 5α‐Reductase Inhibitors Compared with Use of α‐Blockers in Men with Benign Prostatic Hyperplasia: A Population‐Based Study Using the Clinical Practice Research Datalink

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacotherapy

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/phar.1925PMID 28295443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink

  2016cited by this paper
• Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink

  2016cited by this paper
• Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

  2016cited by this paper
• Data Resource Profile: Clinical Practice Research Datalink (CPRD)

  2015cited by this paper
• Depressive symptoms in patients diagnosed with benign prostatic hyperplasia

  2015cited by this paper
• The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression

  2014cited by this paper
• Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.

  2012cited by this paper
• Common mental disorders.

  2012cited by this paper
• Increased risk of depressive disorder following the diagnosis of benign prostatic enlargement: one-year follow-up study.

  2011influential reference
• Depressogenic effects of medications: a review

  2011cited by this paper
• Depression-like behavior of aged male and female mice is ameliorated with administration of testosterone or its metabolites.

  2009cited by this paper
• The present and future perspectives of Modern Rheumatology

  2006cited by this paper
• BMC Clinical Pharmacology BioMed Central

  2006cited by this paper
• Prevalence and predictors of depression in populations of elderly: a review

  2006cited by this paper
• The General Practice Research Database

  2004cited by this paper
• Validity of the General Practice Research Database

  2003cited by this paper
• The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

  2003cited by this paper
• Lipid-lowering drugs and the risk of depression and suicidal behavior.

  2003cited by this paper
• Drug or symptom‐induced depression in men treated with alpha1‐blockers for benign prostatic hyperplasia? A nested case–control study

  2002influential reference
• Depression Circumstantially Related to the Administration of Finasteride for Androgenetic Alopecia

  2002cited by this paper
• Low testosterone levels in elderly men with dysthymic disorder.

  2002cited by this paper
• Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men.

  2001cited by this paper
• The General Practice Research Database. Scientific and Ethical Advisory Group.

  1998cited by this paper
• Further validation of information recorded on a general practitioner based computerized data resource in the united kingdom

  1992cited by this paper
• Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

  1991cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Bioavailable Testosterone and Depressed Mood in Older Men: The Rancho Bernardo Study

  year unknowncited by this paper

• Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement.

  2026cites this paper
• Isolated depressive disorders and suicidality with finasteride use for androgenetic alopecia: A call for enhanced vigilance.

  2025cites this paper
• Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups

  2025cites this paper
• The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population‐based case–control study

  2024cites this paper
• Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study

  2023cites this paper
• Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study

  2023cites this paper
• MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS ATTRIBUTED TO BENIGN PROSTATIC HYPERPLASIA: AUA GUIDELINE

  2023cites this paper
• Prescribing cascades in ambulatory care: A structured synthesis of evidence

  2023cites this paper
• Prescribing Cascades with Recommendations to Prevent or Reverse Them: A Systematic Review

  2023cites this paper
• Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea

  2022cites this paper
• Prescribing cascades in community‐dwelling adults: A systematic review

  2022cites this paper
• Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation

  2021cites this paper
• The connection of 5-alpha reductase inhibitors to the development of depression.

  2021cites this paper
• Marijuana, Alcohol, and ED: Correlations with LUTS/BPH

  2021cites this paper
• Lack of Association Between 5α-Reductase Inhibitors and Depression.

  2020cites this paper
• Long-term mental health and quality of life in women with a history of breast cancer

  2020cites this paper
• Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

  2019cites this paper